James M. Golubieski, president of Foundation Venture Capital Group. See sector focus and contact routes.
James M. Golubieski, president of Foundation Venture Capital Group, invests exclusively in pre-seed and seed-stage health-related technology companies, typically providing $175,000 to $500,000 per deal. His distinctive thesis focuses on commercializing intellectual property from faculty at the University of Medicine and Dentistry of New Jersey (UMDNJ), targeting life sciences such as stem cell therapies for spinal cord injuries, cancer diagnostics, and Alzheimer’s blood tests. Notable portfolio companies include Celvive (spinal cord injury treatment), Actinobac Biomed (hematological malignancies), CellXplore (cancer diagnostics), and Durin Technologies (Alzheimer’s diagnosis).
This profile is part of the StartupFundraising investor database: focus, portfolio history, disclosed location and contact routes, refreshed as new filings and rounds are ingested. Founders use it to check fit before reaching out and to find investors in New Brunswick.
Investors like James M. Golubieski · Full investor directory · Investor access · Company funding database